KR20240038017A - 울로데신 염 - Google Patents

울로데신 염 Download PDF

Info

Publication number
KR20240038017A
KR20240038017A KR1020247005390A KR20247005390A KR20240038017A KR 20240038017 A KR20240038017 A KR 20240038017A KR 1020247005390 A KR1020247005390 A KR 1020247005390A KR 20247005390 A KR20247005390 A KR 20247005390A KR 20240038017 A KR20240038017 A KR 20240038017A
Authority
KR
South Korea
Prior art keywords
ulodecine
hemi
salt
glutarate
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247005390A
Other languages
English (en)
Korean (ko)
Inventor
야오 한
지안펭 차이
주안 리우
퀴우홍 루오
토마스 메흐링
Original Assignee
라에보록 이뮤놀로지 에이지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 라에보록 이뮤놀로지 에이지 filed Critical 라에보록 이뮤놀로지 에이지
Publication of KR20240038017A publication Critical patent/KR20240038017A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/12—Glutaric acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020247005390A 2021-07-20 2022-07-20 울로데신 염 Pending KR20240038017A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2110403.9A GB202110403D0 (en) 2021-07-20 2021-07-20 Ulodesine Salt
GB2110403.9 2021-07-20
PCT/EP2022/070369 WO2023001893A1 (en) 2021-07-20 2022-07-20 Ulodesine salt

Publications (1)

Publication Number Publication Date
KR20240038017A true KR20240038017A (ko) 2024-03-22

Family

ID=77443478

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247005390A Pending KR20240038017A (ko) 2021-07-20 2022-07-20 울로데신 염

Country Status (9)

Country Link
EP (1) EP4373579A1 (https=)
JP (1) JP2024525254A (https=)
KR (1) KR20240038017A (https=)
CN (1) CN117897383A (https=)
AU (1) AU2022314207A1 (https=)
CA (1) CA3226849A1 (https=)
GB (1) GB202110403D0 (https=)
MX (1) MX2024000936A (https=)
WO (1) WO2023001893A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202218782D0 (en) 2022-12-13 2023-01-25 Mehrling Thomas Purine nucleoside phosphorylase inhibitor for metabolic syndrome
WO2025250900A1 (en) * 2024-05-30 2025-12-04 Caamtech, Inc. 4-hydroxy-n,n-diisopropyltryptaminium hydroglutarate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1539783B1 (en) 2002-08-21 2011-04-13 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside phosphorylases and nucleosidases
NZ595590A (en) * 2009-03-24 2013-11-29 Biocryst Pharm Inc Useful pharmaceutical salts of 7-[(3r,4r)-3-hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-one

Also Published As

Publication number Publication date
CA3226849A1 (en) 2023-01-26
CN117897383A (zh) 2024-04-16
EP4373579A1 (en) 2024-05-29
JP2024525254A (ja) 2024-07-11
AU2022314207A1 (en) 2024-01-18
GB202110403D0 (en) 2021-09-01
WO2023001893A4 (en) 2023-03-30
WO2023001893A1 (en) 2023-01-26
MX2024000936A (es) 2024-06-19

Similar Documents

Publication Publication Date Title
US20250382299A1 (en) Short-acting benzodiazepine salts and their polymorphic forms
US8501753B2 (en) Useful pharmaceutical salts of 7-[(3R, 4R)-3-Hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3, 5-dihydro-pyrrolo [3, 2-D] pyrimidin-4-one
CN113226314B (zh) 吡咯烷化合物的晶体
KR20240038017A (ko) 울로데신 염
IL320998A (en) A pharmaceutically acceptable salt of a nitrogen-containing heterocyclic compound, its crystalline form and a method for preparing them
WO2024149365A1 (en) Salts and crystalline forms of compound a, methods of preparation, and uses thereof
CN114072406B (zh) Flna-结合化合物及其盐酸盐的固体多晶型物
US12202834B2 (en) Solid state forms of oclacitinib maleate
CN115916751A (zh) S-吲哚洛尔的有机酸加成盐
TW202128697A (zh) Gabaa正向別構調節劑化合物、其製備方法及用途
JP2021529764A (ja) （ｓ）−（５−シクロブトキシ−２−メチル−６−（１−（ピペリジン−４−イル）−１ｈ−ピラゾール−４−イル）−３，４−ジヒドロキノリン−１（２ｈ）−イル）（シクロプロピル）メタノンの塩およびその固体形態
JP7289017B2 (ja) ピロリジニルウレア誘導体の結晶及びその使用
US20230105181A1 (en) Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1h-pyrazol-4-yl)-3h-imidazo[4,5-b]pyridine
WO2025012389A1 (en) Salts of (s)-1-(1-(3-chlorophenyl)-2-(dimethylamino)ethyl)-4-(5- morpholino-1h-pyrrolo[2,3-b]pyridin-3-yl)pyridin-2(1h)-one, their preparation and their use as erk kinase inhibitors
TW202600556A (zh) Ｋｉｆ１８ａ抑制劑的可藥用鹽、晶型及其製備方法和用途
HK40062038B (zh) 呋喃并咪唑并吡啶类化合物的合成方法、多晶型物、及盐的多晶型物
CN116178277A (zh) 氯比普兰甲磺酸盐晶型及其制备方法
KR20220042143A (ko) 6-클로로-2-에틸-N-(4-(4-(4-(트리플루오로메톡시)페닐)피페리딘-1-일)벤질)이미다조[1,2-a]피리딘-3-카르복사미드의 다양한 형태
JMSMS fluorophenoxyl-N-methylpyridine-2-carboxamide.
HK1234747B (zh) 取代的咪唑并吡啶基-氨基吡啶化合物的盐和多晶型
HK1137739B (en) Short-acting benzodiazepine salts and their polymorphic forms

Legal Events

Date Code Title Description
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P18-X000 Priority claim added or amended

St.27 status event code: A-2-2-P10-P18-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)